AVIR
Atea Pharmaceuticals Inc
NASDAQ: AVIR · HEALTHCARE · BIOTECHNOLOGY
$5.51
+1.47% today
Updated 2026-04-30
Market cap
$435.81M
P/E ratio
—
P/S ratio
1.55x
EPS (TTM)
$-1.94
Dividend yield
—
52W range
$2 – $6
Volume
0.5M
Atea Pharmaceuticals Inc (AVIR) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $48.63M | $351.37M | $192.18M | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | +622.5% | -45.3% | -100.0% | — | — |
| Cost of revenue | $17000.00 | $17000.00 | $38.02M | $29000.00 | $260000.00 | $70.09M | $83.37M | $416000.00 |
| Gross profit | $-17000.00 | $-17000.00 | $10.61M | $351.37M | $-260000.00 | $-70.09M | $-83.37M | $-416000.00 |
| Gross margin | — | — | 21.8% | 100.0% | -0.1% | — | — | — |
| R&D | $6.67M | $10.17M | $38.02M | $167.21M | $81.94M | $132.84M | $145.40M | $148.02M |
| SG&A | $2.80M | $4.44M | $21.64M | $45.78M | $48.71M | $49.92M | $48.85M | $32.86M |
| Operating income | $-9.48M | $-14.61M | $-11.03M | $138.38M | $-130.65M | $-164.16M | $-192.95M | $-180.89M |
| Operating margin | — | — | -22.7% | 39.4% | -68.0% | — | — | — |
| EBITDA | $-9.46M | $-14.59M | $-11.01M | $138.41M | $-130.39M | $-119.59M | $-131.80M | $-180.89M |
| EBITDA margin | — | — | -22.6% | 39.4% | -67.8% | — | — | — |
| EBIT | $-9.48M | $-14.61M | $-11.03M | $138.38M | $-130.65M | $-120.01M | $-132.22M | $-181.30M |
| Interest expense | $0.00 | $0.00 | $83000.00 | $242000.00 | $11.15M | — | — | — |
| Income tax | $413000.00 | $-574000.00 | $-83000.00 | $17.40M | $-3.59M | $1.02M | $925000.00 | — |
| Effective tax rate | -4.8% | 4.1% | 0.8% | 12.6% | 3.0% | -0.8% | -0.6% | 0.0% |
| Net income | $-9.06M | $-13.46M | $-10.95M | $121.19M | $-115.91M | $-135.96M | $-168.38M | $-158.35M |
| Net income growth (YoY) | — | -48.5% | +18.7% | +1207.1% | -195.6% | -17.3% | -23.9% | +6.0% |
| Profit margin | — | — | -22.5% | 34.5% | -60.3% | — | — | — |